For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Astria Therapeutics Inc’s stock clocked out at $9.75, down -7.50% from its previous closing price of $10.54. In other words, the price has decreased by -$7.50 from its previous closing price. On the day, 1.24 million shares were traded. ATXS stock price reached its highest trading level at $10.64 during the session, while it also had its lowest trading level at $9.484.
Ratios:
To gain a deeper understanding of ATXS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.73 and its Current Ratio is at 21.73. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on March 28, 2023, initiated with a Outperform rating and assigned the stock a target price of $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Morabito Christopher sold 10,000 shares for $13.59 per share. The transaction valued at 135,939 led to the insider holds 0 shares of the business.
PERCEPTIVE ADVISORS LLC bought 2,481,350 shares of ATXS for $29,999,522 on Feb 01 ’24. The Director now owns 4,873,721 shares after completing the transaction at $12.09 per share. On Jan 29 ’24, another insider, Morabito Christopher, who serves as the Chief Medical Officer of the company, sold 9,200 shares for $11.15 each. As a result, the insider received 102,552 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATXS now has a Market Capitalization of 535305216 and an Enterprise Value of 384427840.
Stock Price History:
The Beta on a monthly basis for ATXS is 0.82, which has changed by -0.20473081 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, ATXS has reached a high of $16.90, while it has fallen to a 52-week low of $4.26. The 50-Day Moving Average of the stock is -28.57%, while the 200-Day Moving Average is calculated to be 8.50%.
Shares Statistics:
It appears that ATXS traded 1.05M shares on average per day over the past three months and 708610 shares per day over the past ten days. A total of 54.90M shares are outstanding, with a floating share count of 44.56M. Insiders hold about 18.84% of the company’s shares, while institutions hold 69.25% stake in the company. Shares short for ATXS as of 1711584000 were 5059726 with a Short Ratio of 4.84, compared to 1709164800 on 1696784. Therefore, it implies a Short% of Shares Outstanding of 5059726 and a Short% of Float of 9.87.
Earnings Estimates
The current assessment of Astria Therapeutics Inc (ATXS) involves the perspectives of 5 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.36 for the current quarter, with a high estimate of -$0.31 and a low estimate of -$0.41, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.29 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.22 and -$1.91 for the fiscal current year, implying an average EPS of -$1.55. EPS for the following year is -$1.74, with 5 analysts recommending between -$1.41 and -$2.09.
